Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LCQ908A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LCQ908 Dose 1 | EXPERIMENTAL | - |
| LCQ908 Dose 2 | EXPERIMENTAL | - |
| LCQ908 Dose 3 | EXPERIMENTAL | - |
| LCQ908 Dose 4 | EXPERIMENTAL | - |
| LCQ908 Dose 5 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Sitagliptin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LCQ908A | DRUG | - |
| Placebo | DRUG | - |
| Sitagliptin | DRUG | - |
| metformin | DRUG | - |
Inclusion Criteria: * HbA1c from 7.0-10.0%, Stable Metformin dose Exclusion Criteria: * CHF Class III-IV, Liver disease Other protocol-defined inclusion/exclusion criteria may apply
LCQ908A is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is intended to address the metabolic condition, though its exact mechanism of action is not specified.
LCQ908A is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes Mellitus.
LCQ908A is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
LCQ908A has one completed clinical trial, identified as NCT00901979, titled 'A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)'. This Phase 2, randomized, double-blind, placebo-controlled study enrolled 693 participants across the United States, Canada, Italy, Poland, and Puerto Rico.
LCQ908A is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The completed Phase 2 trial was a randomized, double-blind, placebo-controlled study, but the drug has not yet received marketing authorization from regulatory agencies.